Kevin Koch, Ph.D., President and Chief Scientific Officer, Array BioPharma Inc.
Kevin Koch, Ph.D., received a Bachelor of Science degree from State University of New York at Stony Brook with majors in Chemistry and Biochemistry. After working at Ciba-Giegy Corporation in the Chemical Process Research Group, he studied at the University of Rochester where he received a Ph.D. in synthetic organic chemistry working with Professor Andrew S. Kende. He was awarded both the Sherman Clarke Fellowship and Elon Huntington Hooker Fellowship for his research. In 1988, Kevin moved to Pfizer Central Research and was promoted to Senior Research Investigator-Project Coordinator for the Cellular Migration and Immunology Project Teams. In 1995, he joined Amgen Inc. as Associate Director of Medicinal Chemistry and project leader for the Protease Inhibitor and New Leads project teams. In 1998, Kevin along with Anthony Piscopio, K.C. Nicolaou and David Snitman founded Array BioPharma, a drug discovery company integrating new technologies in the fields of medicinal chemistry, biologic screening, structure based drug design and information management. He currently holds the position of President and Chief Scientific Officer. In the field of organic synthesis, he has published in the areas of the intramolecular ene reaction of N-acyl imines, oxidative radical couplings of phenolates and enolates, the total synthesis of the anti-tumor antibiotic Lankacidin C, methods in palladium catalyzed chemistry and combinatorial synthesis of peptidomimetics. In the field of medicinal chemistry, he has published in the areas of leukotriene antagonists, macrolide immune-suppressant agents and metalloproteinase inhibitors. He is the author or co-author of over 40 publications and 16 patents. His current research interests include combinatorial chemistry, cytokine modulation, and kinase inhibition.